Logo

Call us today 212-583-0100

ir@enzo.com    

  • Home
  • Corporate
    • Investor Information
    • About Us
    • Officers & Directors
    • Press Releases
    • Careers
  • Therapeutics
    • About ENZO Therapeutics
      • Overview
      • Our Mission
      • Our Strategy
      • Partnering
      • Maps and Directions
      • Contact Us
    • Therapeutic Market
      • Overview
      • Inflammatory Bowel Disease
      • Uveitis
      • HIV
      • Bone Disorders
      • Diabetes
    • Technologies
      • Immune Regulation
      • Gene Technology
      • Cell Signaling Modulation
    • Pipeline
      • Overview
      • Cell Signaling Modulation
        • Diabetes
        • Preclinical Studies for Bone Disorders
      • Immune Regulation
        • Alequel ™
        • Optiquel ™
      • Gene Technology
        • Stealth Vector™ HGTV43™
  • Clinical Labs
  • Life Sciences
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Nov 06, 2023 8:00am EST

ENZO BIOCHEM REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 RESULTS AND PROVIDES BUSINESS UPDATE

Oct 30, 2023 4:15pm EDT

Steven J. Pully Appointed to Enzo Biochem’s Board of Directors

Sep 06, 2023 8:30am EDT

Enzo Biochem Announces Departure of Hamid Erfanian and Appointment of Kara Cannon as Interim CEO

Jul 24, 2023 4:27pm EDT

Enzo Biochem Completes Sale of Clinical Laboratory to Labcorp

Jun 14, 2023 7:21pm EDT

Enzo Biochem Reports Third Quarter Fiscal Year 2023 Financial Results

May 22, 2023 9:20am EDT

Enzo Biochem Reports Significant Progress towards Completing the Clinical Lab Asset Sale

Apr 24, 2023 4:05pm EDT

Enzo Biochem, Inc. Announces Date of Special Meeting of Shareholders

Mar 21, 2023 9:43am EDT

Enzo Biochem Reports Second Quarter Fiscal Year 2023 Financial Results

Mar 16, 2023 4:30pm EDT

Enzo Biochem Agrees to Sell Clinical Laboratory to Labcorp

Dec 12, 2022 5:29pm EST

Enzo Biochem Reports First Quarter Fiscal Year 2023 Financial Results and Provides Business Update

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …33
  • Next
RSS
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed

Meta

  • Privacy Policy
  • Intellectual Property
  • Safe Harbor Statement
  • HIPAA Policy
  • Web Feedback

Contact us

Enzo Biochem Executive Offices
81 Executive Blvd, Suite 3
Farmingdale, NY
11735
USA

212-583-0100

info@enzo.com

Copyright ©2023 Enzo Biochem Inc.